Alexion Pharmaceuticals (ALXN +6.5%) is up on double normal in apparent response to rumors that Biogen (BIIB +0.0%) may be eyeing the company.
ALXN is currently valued at $25.4B. Q2 revenues were ~$1.44B led by Soliris: $975.5M (-0.5%); Ultomiris: $251.1M (+363.3%); Strensiq: $184.3M (+30.4%) and Kanuma: $33.6M (+28.2%). Cash flow ops was up 38% to ~$1.34B.
2020 outlook: Revenues: $5.55B – 5.60B; Soliris/Ultomiris sales: $4.73B – 4.76B; non-GAAP EPS: $10.65 – 10.95.
https://seekingalpha.com/news/3614287-alexion-pharma-up-7-on-rumored-biogen-interest
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.